# Pamela L. Wolters

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pamela-l-wolters/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,751 |
| Field | Neurofibromatosis and Schwannoma Cases |
| h-index | 48 |
| i10-index | 100 |
| Last Known Institution | National Institutes of Health |
| OpenAlex ID | https://openalex.org/A5065611220 |
| ORCID iD | 0000-0001-9319-6281 |
| Works | 154 |

## Researcher papers

- [CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy](https://scholariq.org/papers/cd22-targeted-car-t-cells-induce-remission-in-b-all-that-is-naive-or-resistant/)
- [Neurofibromatosis type 1](https://scholariq.org/papers/neurofibromatosis-type-1/)
- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas](https://scholariq.org/papers/activity-of-selumetinib-in-neurofibromatosis-type-1-related-plexiform/)
- [CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial](https://scholariq.org/papers/cd4-cd8-t-cell-selection-affects-chimeric-antigen-receptor-car-t-cell-potency/)
- [Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL](https://scholariq.org/papers/long-term-follow-up-of-cd19-car-t-cell-therapy-in-children-and-young-adults-with/)
- [Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection](https://scholariq.org/papers/dideoxyinosine-in-children-with-symptomatic-human-immunodeficiency-virus/)
- [CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR](https://scholariq.org/papers/cd19-22-car-t-cells-in-children-and-young-adults-with-b-all-phase-1-results-and/)
- [Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum](https://scholariq.org/papers/safety-and-efficacy-of-low-dose-sirolimus-in-the-pik3ca-related-overgrowth/)
- [NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas](https://scholariq.org/papers/nf106-a-neurofibromatosis-clinical-trials-consortium-phase-ii-trial-of-the-mek/)
- [A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib](https://scholariq.org/papers/a-mixed-methods-study-of-medication-adherence-in-adults-with-neurofibromatosis/)

## Researcher topics

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)
- [HIV/AIDS Research and Interventions](https://scholariq.org/topics/hiv-aids-research-and-interventions/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [HIV Research and Treatment](https://scholariq.org/topics/hiv-research-and-treatment/)
- [Tuberous Sclerosis Complex Research](https://scholariq.org/topics/tuberous-sclerosis-complex-research/)

## Researcher university

- [National Institutes of Health](https://scholariq.org/institutions/national-institutes-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.